Affine blocking sets, three-dimensional codes and the Griesmer bound

Simeon Ball,Elisa Montanucci

DOI: https://doi.org/10.1016/j.disc.2006.09.011

IF: 0.961

2007-06-01

Discrete Mathematics

Abstract:

What problem does this paper attempt to address?

DRAFT DRAFT 1 Representing and Reasoning with Correlated Effects in Probabilistic Causal Models

J. Lemmer

Abstract:This paper introduces a new form of knowledge representation for probabilistic Uncertain Causal Models. This representation allows for correlations among effects to be more easily represented than in chain rule based models, such as standard Bayesian Networks (BN's). The importance of effect correlations has been recognized since the early days of computerized causal models, especially in the medical community. Currently, when effect correlations are important, techniques based on the Bahadur expansion are usually used rather than techniques based on Bayesian Networks. This paper adds a new knowledge structure to Bayesian Networks capable of representing effect correlation. Bayesian Networks now use Conditional Probability Tables (CPT‟s) to represent uncertain causal knowledge. This paper defines an additional representation we call Effect Probability Tables (EPT's). Unlike CPT‟s, EPT‟s can efficiently represent effect correlations. We analyze the relation between EPT‟s and CPT‟s and show them to be duals when effects are conditionally independent and causes are causally independent. We present an algorithm for using both representations in the same model without requiring these independence assumptions. We do claim that in some domains, the parameters for EPT‟s are more natural to obtain than the parameters for CPT's especially when subjective parameters are to be elicited experts. We claim that EPT's can result in better models especially when effect correlations are important. No claim is made that there are joint probability distributions, which cannot be modeled using just CPT‟s. But we do claim that the structure and parameterization of models built with both representations can be much more natural to experts. The paper also shows by example how modeling effect correlations can produce significantly different inference results than if these correlations were assumed away, as is common Bayesian Network practice today. Since the paper provides techniques for combining both CPT's and EPT's in the same model, synergies among causes, now conveniently modeled using CPT's, can be combined with effect correlations, conveniently modeled using EPT's, to provide more accurate, powerful and satisfactory models.
[Analysis of the Mutations of BRCA1 in 9 Familiar Breast Cancer Patients].

Shanming Deng,Yi Wang,Yang Ke,Guangwei Xu

DOI: https://doi.org/10.3969/j.issn.1000-9760.2011.02.007

2003-01-01

Abstract:OBJECTIVETo analyze the mutations of BRCA1 in 9 Chinese familiar breast cancer patients.METHODSPeripheral blood samples were obtained from 9 patients enrolled from 9 breast cancer families, one normal control, 32 sporadic breast cancer patients and 33 normal donors. DNA extracted from lymphocytes was amplified by polymerase chain reaction (PCR). The 22 exons and partial introns of BRCA1 were screened by PCR-denaturing high performance liquid chromatography (PCR-DHPLC) and confirmed by direct sequencing.RESULTSAmong these 9 familiar breast cancer patients, a deleterious mutation was detected in one case in exon 11 (3870delTGTC) which was a 4-base deletion and caused a frameshift in turn. One novel and unique amino acid substitution (E867R) was detected in one case. Eight patients were detected to have a known variation in intron 18 (IVS18 + 65G-->A), and the ratio of this variation detected was 88.9% (8/9). The ratio of this variation was 37.5% (12/32) in sporadic breast cancer patients or 33.3% (11/33) in normal control. This variation was found to be accompanied all the time with a known missense variation in exon 11 (P871L) and a polymorphism in intron 9 (IVS8-57delT). Those three variants were also detected in homozygous in one case, which implies the linkage of the 3 sites. The linkage had not been reported. Two patients had been found with a known polymorphism in exon 13 (S1436S). Another known polymorphism was found in one case (L771L). In addition, intronic variants (IVS2 + 48C-->T, IVS2 + 133C-->T, IVS12 + 112C-->A) were detected.CONCLUSIONThe mutations of BRCA1 in Chinese familiar breast cancer patients are different from the hot spots reported in Caucasian and Jewish. It is important that further study be conducted to seek for specific mutations of this gene or other possible relevant genes in Chinese familiar breast cancer patients.
Youth with disabilities' perspectives of the environment and participation: a qualitative meta-synthesis.

Jessica M. Kramer,S. Olsen,M. Mermelstein,A. Balcells,K. Liljenquist

DOI: https://doi.org/10.1111/j.1365-2214.2012.01365.x

2012-11-01

Abstract:Meta-syntheses can enhance our knowledge regarding the impact of the environment on the participation of youth with disabilities and generate theoretical frameworks to inform policy and best practices. The purpose of this study was to describe school-aged youth with disabilities' perspectives regarding the impact of the environment and modifications on their participation. A meta-synthesis systematically integrates qualitative evidence from multiple studies. Six databases were searched and 1287 citations reviewed for inclusion by two independent raters; 15 qualitative articles were selected for inclusion. Two independent reviewers evaluated the quality of each study and coded the results section. Patterns between codes within and across articles were examined using a constant comparative approach. Environments may be more or less inclusive for youth with disabilities depending upon others' understanding of individual abilities and needs, youth involvement in decisions about accommodations, and quality of services and policies. Youth implemented strategies to negotiate environmental barriers and appraised the quality of their participation based on the extent to which they engaged alongside peers. This meta-synthesis generated a framework illustrating the relationship between the environment, modifications and participation, and provided a conceptualization of participation grounded in the lived experiences of youth with disabilities. Findings reveal gaps in current knowledge and highlight the importance of involving youth with disabilities in decision making.
A Genome-Wide Association Study Identifies a New Ovarian Cancer Susceptibility Locus on 9P22.2.

Honglin Song,Susan J Ramus,Jonathan Tyrer,Kelly L Bolton,Aleksandra Gentry-Maharaj,Eva Wozniak,Hoda Anton-Culver,Jenny Chang-Claude,Daniel W Cramer,Richard DiCioccio,Thilo Dörk,Ellen L Goode,Marc T Goodman,Joellen M Schildkraut,Thomas Sellers,Laura Baglietto,Matthias W Beckmann,Jonathan Beesley,Jan Blaakaer,Michael E Carney,Stephen Chanock,Zhihua Chen,Julie M Cunningham,Ed Dicks,Jennifer A Doherty,Matthias Dürst,Arif B Ekici,David Fenstermacher,Brooke L Fridley,Graham Giles,Martin E Gore,Immaculata De Vivo,Peter Hillemanns,Claus Hogdall,Estrid Hogdall,Edwin S Iversen,Ian J Jacobs,Anna Jakubowska,Dong Li,Jolanta Lissowska,Jan Lubiński,Galina Lurie,Valerie McGuire,John McLaughlin,Krzysztof Mędrek,Patricia G Moorman,Kirsten Moysich,Steven Narod,Catherine Phelan,Carole Pye,Harvey Risch,Ingo B Runnebaum,Gianluca Severi,Melissa Southey,Daniel O Stram,Falk C Thiel,Kathryn L Terry,Ya-Yu Tsai,Shelley S Tworoger,David J Van Den Berg,Robert A Vierkant,Shan Wang-Gohrke,Penelope M Webb,Lynne R Wilkens,Anna H Wu,Hannah Yang,Wendy Brewster,Argyrios Ziogas,Richard Houlston,Ian Tomlinson,Alice S Whittemore,Mary Anne Rossing,Bruce A J Ponder,Celeste Leigh Pearce,Roberta B Ness,Usha Menon,Susanne Krüger Kjaer,Jacek Gronwald,Montserrat Garcia-Closas,Peter A Fasching,Douglas F Easton,Georgia Chenevix-Trench,Andrew Berchuck,Paul D P Pharoah,Simon A Gayther

DOI: https://doi.org/10.1038/ng.424

2009-01-01

Abstract:Epithelial ovarian cancer has a major heritable component, but the known susceptibility genes explain less than half the excess familial risk. We performed a genome-wide association study (GWAS) to identify common ovarian cancer susceptibility alleles. We evaluated 507,094 SNPs genotyped in 1,817 cases and 2,353 controls from the UK and approximately 2 million imputed SNPs. We genotyped the 22,790 top ranked SNPs in 4,274 cases and 4,809 controls of European ancestry from Europe, USA and Australia. We identified 12 SNPs at 9p22 associated with disease risk (P < 10(-8)). The most significant SNP (rs3814113; P = 2.5 x 10(-17)) was genotyped in a further 2,670 ovarian cancer cases and 4,668 controls, confirming its association (combined data odds ratio (OR) = 0.82, 95% confidence interval (CI) 0.79-0.86, P(trend) = 5.1 x 10(-19)). The association differs by histological subtype, being strongest for serous ovarian cancers (OR 0.77, 95% CI 0.73-0.81, P(trend) = 4.1 x 10(-21)).
Identification and functional analysis of 9p24 amplified genes in human breast cancer

Wu, J,Liu, S,Liu, G,Dombkowski, A,Abrams, J,Martin-Trevino, R,Wicha, M S,Ethier, S P,Yang, Z-Q

DOI: https://doi.org/10.1038/onc.2011.227

IF: 8.756

2012-01-01

Oncogene

Abstract:Previously, our group identified a novel amplicon at chromosome 9p24 in human esophageal and breast cancers, and cloned the novel gene, GASC1 (gene amplified in squamous cell carcinoma 1, also known as JMJD2C/KDM4C), from this amplicon. GASC1 is a histone demethylase involved in the deregulation of histone methylation in cancer cells. In the current study, we aimed to comprehensively characterize the genes in the 9p24 amplicon in human breast cancer. We performed extensive genomic analyses on a panel of cancer cell lines and narrowed the shortest region of overlap to approximately 2 Mb. Based on statistical analysis of copy number increase and overexpression, the 9p24 amplicon contains six candidate oncogenes. Among these, four genes (GASC1 UHRF2, KIAA1432 and C9orf123) are overexpressed only in the context of gene amplification while two genes (ERMP1 and IL33) are overexpressed independent of the copy number increase. We then focused our studies on the UHRF2 gene, which has a potential involvement in both DNA methylation and histone modification. Knocking down UHRF2 expression inhibited the growth of breast cancer cells specifically with 9p24 amplification. Conversely, ectopic overexpression of UHRF2 in non-tumorigenic MCF10A cells promoted cell proliferation. Furthermore, we demonstrated that UHRF2 has the ability to suppress the expression of key cell-cycle inhibitors, such as p16INK4a, p21Waf1/Cip1 and p27Kip1. Taken together, our studies support the notion that the 9p24 amplicon contains multiple oncogenes that may integrate genetic and epigenetic codes and have important roles in human tumorigenesis.
Amplification of PVT1 Contributes to the Pathophysiology of Ovarian and Breast Cancer.

Yinghui Guan,Wen-Lin Kuo,Jackie L. Stilwell,Hirokuni Takano,Anna V. Lapuk,Jane Fridlyand,Jian-Hua Mao,Mamie Yu,Melinda A. Miller,Jennifer L. Santos,Steve E. Kalloger,Joseph W. Carlson,David G. Ginzinger,Susan E. Celniker,Gordon B. Mills,David G. Huntsman,Joe W. Gray

DOI: https://doi.org/10.1158/1078-0432.ccr-06-2882

IF: 13.801

2007-01-01

Clinical Cancer Research

Abstract:Abstract Purpose: This study was designed to elucidate the role of amplification at 8q24 in the pathophysiology of ovarian and breast cancer because increased copy number at this locus is one of the most frequent genomic abnormalities in these cancers. Experimental Design: To accomplish this, we assessed the association of amplification at 8q24 with outcome in ovarian cancers using fluorescence in situ hybridization to tissue microarrays and measured responses of ovarian and breast cancer cell lines to specific small interfering RNAs against the oncogene MYC and a putative noncoding RNA, PVT1, both of which map to 8q24. Results: Amplification of 8q24 was associated with significantly reduced survival duration. In addition, small interfering RNA–mediated reduction in either PVT1 or MYC expression inhibited proliferation in breast and ovarian cancer cell lines in which they were both amplified and overexpressed but not in lines in which they were not amplified/overexpressed. Inhibition of PVT1 expression also induced a strong apoptotic response in cell lines in which it was overexpressed but not in lines in which it was not amplified/overexpressed. Inhibition of MYC, on the other hand, did not induce an apoptotic response in cell lines in which MYC was amplified and overexpressed. Conclusions: These results suggest that MYC and PVT1 contribute independently to ovarian and breast pathogenesis when overexpressed because of genomic abnormalities. They also suggest that PVT1-mediated inhibition of apoptosis may explain why amplification of 8q24 is associated with reduced survival duration in patients treated with agents that act through apoptotic mechanisms.
High-Resolution Genomic And Expression Analyses Of Copy Number Alterations In Breast Tumors

Peter M. Haverty,Jane Fridlyand,Li Li,Gad Getz,Rameen Beroukhim,Scott Lohr,Thomas D. Wu,Guy Cavet,Zemin Zhang,John Chant

DOI: https://doi.org/10.1002/gcc.20558

2008-01-01

Abstract:Analysis of recurrent DNA amplification can lead to the identification of cancer driver genes, but this process is often hampered by the low resolution of existing copy number analysis platforms. Fifty-one breast tumors were profiled for copy number alterations (CNAs) with the high-resolution Affymetrix 500K SNP array. These tumors were also expression-profiled and surveyed for mutations in selected genes commonly mutated in breast cancer (TP53, CDKN2A, ERBB2, KRAS, PIK3CA, PTEN). Combined analysis of common CNAs and mutations revealed putative associations between features. Analysis of both the prevalence and amplitude of CNAs defined regions of recurrent alteration. Compared with previous array comparative genomic hybridization studies, our analysis provided boundaries for frequently altered regions that were approximately one-fourth the size, greatly reducing the number of potential alteration-driving genes. Expression data from matched tumor samples were used to further interrogate the functional relevance of genes located in recurrent amplicons. Although our data support the importance of some known driver genes such as ERBB2, refined amplicon boundaries at other locations, such as 8p11-12 and 11q13.5-q14.2, greatly reduce the number of potential driver genes and indicate alternatives to commonly suggested driver genes in some cases. For example, the previously reported recurrent amplification at 17q23.2 is reduced to a 249 kb minimal region containing the putative driver RPS6KB1 as well as the putative oncogenic microRNA mir-21. High-resolution copy number analysis provides refined insight into many breast cancer amplicons and their relationships to gene expression, point mutations and breast cancer subtype classifications. This article contains Supplementary Material available at http:// www.interscience.wiley.com/jpages/1045-2257/suppmat. (C) 2008 Wiley-Liss, Inc.
A novel RBBP8(p.E281*) germline mutation is a predisposing mutation in familial hereditary cancer syndrome

Jinhua Yan,Jinzheng Wu,Yang Wang,Xiaotang Di,Hao Jiang,Doudou Wen,Duo Li,Shubing Zhang

DOI: https://doi.org/10.1007/s00109-023-02354-z

2023-08-25

Journal of Molecular Medicine

Abstract:Screening tumor susceptibility genes helps in identifying powerful biomarkers for hereditary cancer monitoring, prevention, and diagnosis, providing opportunities for understanding potential molecular mechanisms and biomarkers for the precise treatment of hereditary cancer syndromes. Whole-exome sequencing of blood and bioinformatics analysis uncovered a novel RBBP8(p.E281*) germline mutation in a family with hereditary cancer syndrome, which was verified by Sanger sequencing. Cell proliferation, colony formation, cell migration, and in vivo tumorigenesis were investigated by CCK8, colony formation, Transwell, and in vivo xenograft assays. Protein localization and interaction were detected by immunofluorescence, nuclear and cytoplasmic protein extraction kits, and Co-IP. A new heterozygous germline mutation of the RBBP8(p.E281*) gene was found to be associated with familial hereditary cancer syndrome. RBBP8-WT was mainly detected in the nucleus and interacts with BRCA1. In contrast, RBBP8(p.E281*) is mainly located in the cytoplasm, with no interaction with BRCA1. RBBP8(p.E281*) variant plays an oncogenic role in the cytoplasm in addition to its loss of function in the nucleus, which promotes breast cancer proliferation, in vivo tumorigenesis, and migration. Compared with the control group, RBBP8(p.E281*) showed elevated cell death in response to cisplatin and olaparib treatment. A novel RBBP8(p.E281*) germline mutation was identified from familial hereditary cancer syndrome. RBBP8(p.E281*) is not able to enter the nucleus or interact with BRCA1 through the lost binding motif, and RBBP8(p.E281*) variant appears to promote tumorigenesis in the cytoplasm in addition to its loss of function in the nucleus. RBBP8(p.E281*) variant may promote tumor susceptibility and serve as a precision medicine biomarker in familial hereditary cancer syndrome.

genetics & heredity,medicine, research & experimental
5' Region Large Genomic Rearrangements in the BRCA1 Gene in French Families: Identification of a Tandem Triplication and Nine Distinct Deletions with Five Recurrent Breakpoints

Sandrine M Caputo,Dominique Telly,Adrien Briaux,Julie Sesen,Maurizio Ceppi,Françoise Bonnet,Violaine Bourdon,Florence Coulet,Laurent Castera,Capucine Delnatte,Agnès Hardouin,Sylvie Mazoyer,Inès Schultz,Nicolas Sevenet,Nancy Uhrhammer,Céline Bonnet,Anne-Françoise Tilkin-Mariamé,Claude Houdayer,Virginie Moncoutier,Catherine Andrieu,French Covar Group Collaborators,Ivan Bièche,Marc-Henri Stern,Dominique Stoppa-Lyonnet,Rosette Lidereau,Christine Toulas,Etienne Rouleau

DOI: https://doi.org/10.3390/cancers13133171

2021-06-25

Abstract:Background: Large genomic rearrangements (LGR) in BRCA1 consisting of deletions/duplications of one or several exons have been found throughout the gene with a large proportion occurring in the 5' region from the promoter to exon 2. The aim of this study was to better characterize those LGR in French high-risk breast/ovarian cancer families. Methods: DNA from 20 families with one apparent duplication and nine deletions was analyzed with a dedicated comparative genomic hybridization (CGH) array, high-resolution BRCA1 Genomic Morse Codes analysis and Sanger sequencing. Results: The apparent duplication was in fact a tandem triplication of exons 1 and 2 and part of intron 2 of BRCA1, fully characterized here for the first time. We calculated a causality score with the multifactorial model from data obtained from six families, classifying this variant as benign. Among the nine deletions detected in this region, eight have never been identified. The breakpoints fell in six recurrent regions and could confirm some specific conformation of the chromatin. Conclusions: Taken together, our results firmly establish that the BRCA1 5' region is a frequent site of different LGRs and highlight the importance of the segmental duplication and Alu sequences, particularly the very high homologous region, in the mechanism of a recombination event. This also confirmed that those events are not systematically deleterious.
Alu–Mediated Duplication and Deletion of Exon 11 Are Frequent Mechanisms of PALB2 Inactivation, Predisposing Individuals to Hereditary Breast–Ovarian Cancer Syndrome

Diletta Sidoti,Valeria Margotta,Diletta Calosci,Erika Fiorentini,Costanza Bacci,Francesca Gensini,Laura Papi,Marco Montini

DOI: https://doi.org/10.3390/cancers16234022

2024-11-30

Cancers

Abstract:Background/Objective: Large genomic rearrangements of PALB2 gene, particularly deletions and duplications, have been linked to hereditary breast–ovarian cancer. Our research specifically focuses on delineating the intronic breakpoints associated with rearrangements of PALB2 exon 11, which is crucial for understanding the mechanisms underlying these genomic changes in patients with hereditary breast and ovarian syndrome. Methods: By using next-generation sequencing, we identified one duplication and three deletions of PALB2 exon 11, confirmed by Multiplex Ligation-Dependent Probe Amplification analysis. To assess the impact on transcription and potential splicing issues, reverse-transcription PCR was performed on patients' RNA. For the detailed characterization of intronic breakpoints, the primer walking approach and long-range PCR were implemented, followed by Sanger sequencing. Results: Our analysis revealed a tandem duplication of 5134 base pairs (bp) mediated by AluY repeats located in introns 10 and 11, respectively. Moreover, identical deletions were identified in three unrelated patients, encompassing an approximate 8050 bp region mediated by AluSx elements. Both genomic alterations resulted in a truncated PALB2 protein due to the introduction of a premature stop codon. Conclusions: This study underscores the remarkable instability of intronic regions flanking exon 11 of PALB2 and identifies a previously unreported hotspot involving Alu repeats with very high sequence homology in introns 10 and 11 of the gene. Our findings suggest avenues for further research, such as investigating the prevalence of similar genomic rearrangements in larger cohorts and exploring functional studies to understand how these alterations contribute to hereditary breast cancer pathogenesis.

oncology
Functional Analysis and Fine Mapping of the 9p22.2 Ovarian Cancer Susceptibility Locus

Melissa A Buckley,Nicholas T Woods,Jonathan P Tyrer,Gustavo Mendoza-Fandiño,Kate Lawrenson,Dennis J Hazelett,Hamed S Najafabadi,Anxhela Gjyshi,Renato S Carvalho,Paulo C Lyra Jr,Simon G Coetzee,Howard C Shen,Ally W Yang,Madalene A Earp,Sean J Yoder,Harvey Risch,Georgia Chenevix-Trench,Susan J Ramus,Catherine M Phelan,Gerhard A Coetzee,Houtan Noushmehr,Timothy R Hughes,Thomas A Sellers,Ellen L Goode,Paul D Pharoah,Simon A Gayther,Alvaro N A Monteiro,Ovarian Cancer Association Consortium

DOI: https://doi.org/10.1158/0008-5472.CAN-17-3864

2019-02-01

Abstract:Genome-wide association studies have identified 40 ovarian cancer risk loci. However, the mechanisms underlying these associations remain elusive. In this study, we conducted a two-pronged approach to identify candidate causal SNPs and assess underlying biological mechanisms at chromosome 9p22.2, the first and most statistically significant associated locus for ovarian cancer susceptibility. Three transcriptional regulatory elements with allele-specific effects and a scaffold/matrix attachment region were characterized and, through physical DNA interactions, BNC2 was established as the most likely target gene. We determined the consensus binding sequence for BNC2 in vitro, verified its enrichment in BNC2 ChIP-seq regions, and validated a set of its downstream target genes. Fine-mapping by dense regional genotyping in over 15,000 ovarian cancer cases and 30,000 controls identified SNPs in the scaffold/matrix attachment region as among the most likely causal variants. This study reveals a comprehensive regulatory landscape at 9p22.2 and proposes a likely mechanism of susceptibility to ovarian cancer. SIGNIFICANCE: Mapping the 9p22.2 ovarian cancer risk locus identifies BNC2 as an ovarian cancer risk gene.See related commentary by Choi and Brown, p. 439.
A Molecular Characterization of the Allelic Expression of the BRCA1 Founder Δ9–12 Pathogenic Variant and Its Potential Clinical Relevance in Hereditary Cancer

Julieta Dominguez-Ortiz,Rosa M. Álvarez-Gómez,Rogelio Montiel-Manríquez,Alberto Cedro-Tanda,Nicolás Alcaraz,Clementina Castro-Hernández,Luis Bautista-Hinojosa,Laura Contreras-Espinosa,Leda Torres-Maldonado,Verónica Fragoso-Ontiveros,Yuliana Sánchez-Contreras,Rodrigo González-Barrios,Marcela Angélica De la Fuente-Hernández,María de la Luz Mejía-Aguayo,Ulises Juárez-Figueroa,Alejandra Padua-Bracho,Rodrigo Sosa-León,Gabriela Obregon-Serrano,Silvia Vidal-Millán,Paulina María Núñez-Martínez,Abraham Pedroza-Torres,Sergio Nicasio-Arzeta,Alfredo Rodríguez,Fernando Luna,Fernanda Cisneros-Soberanis,Sara Frías,Cristian Arriaga-Canon,Luis A. Herrera-Montalvo

DOI: https://doi.org/10.3390/ijms25126773

IF: 5.6

2024-06-21

International Journal of Molecular Sciences

Abstract:Hereditary breast and ovarian cancer (HBOC) syndrome is a genetic condition that increases the risk of breast cancer by 80% and that of ovarian cancer by 40%. The most common pathogenic variants (PVs) causing HBOC occur in the BRCA1 gene, with more than 3850 reported mutations in the gene sequence. The prevalence of specific PVs in BRCA1 has increased across populations due to the effect of founder mutations. Therefore, when a founder mutation is identified, it becomes key to improving cancer risk characterization and effective screening protocols. The only founder mutation described in the Mexican population is the deletion of exons 9 to 12 of BRCA1 (BRCA1Δ9–12), and its description focuses on the gene sequence, but no transcription profiles have been generated for individuals who carry this gene. In this study, we describe the transcription profiles of cancer patients and healthy individuals who were heterozygous for PV BRCA1Δ9–12 by analyzing the differential expression of both alleles compared with the homozygous BRCA1 control group using RT–qPCR, and we describe the isoforms produced by the BRCA1 wild-type and BRCA1Δ9–12 alleles using nanopore long-sequencing. Using the Kruskal–Wallis test, our results showed a similar transcript expression of the wild-type allele between the healthy heterozygous group and the homozygous BRCA1 control group. An association between the recurrence and increased expression of both alleles in HBOC patients was also observed. An analysis of the sequences indicated four wild-type isoforms with diagnostic potential for discerning individuals who carry the PV BRCA1Δ9–12 and identifying which of them has developed cancer.

biochemistry & molecular biology,chemistry, multidisciplinary
CCNE1 amplification as marker of poor prognosis and novel therapeutic target in advanced breast cancer.

Antonio Marra,Pier Selenica,Yingjie Zhu,Anton Safonov,Pedram Razavi,Anne Roulston,Maria Koehler,Giuseppe Curigliano,Dara S. Ross,Britta Weigelt,Jorge Reis-Filho,Alison M. Schram,Sarat Chandarlapaty,Ezra Rosen

DOI: https://doi.org/10.1200/jco.2024.42.16_suppl.1040

IF: 45.3

2024-05-31

Journal of Clinical Oncology

Abstract:1040 Background: Cyclin E1 (CCNE1) overexpression or gene amplification is linked to dismal outcomes in various tumors, including breast cancer (BC). Recent studies suggest that CCNE1 amplification is a potential target for new synthetic lethality-based treatments, including CDK2-selective and PKMYT1 inhibition. This study explores the clinical and genomic characteristics of CCNE1-amplified BCs. Methods: We analyzed genomic and clinical data from consecutive BCs that underwent clinical tumor-normal targeted panel sequencing (MSK-IMPACT) between April 2014 and December 2021. Allele-specific copy number, including CCNE1 amplification, and fraction genome altered (FGA) were calculated by FACETS. Mutual exclusivity and co-occurrence analyses were performed using CoMEt. Benjamini–Hochberg method for multiple testing correction (q) was applied. Real-world progression-free survival (rwPFS) was assessed by the Kaplan Meier method and Cox models, focusing on patients with available pre-treatment samples. Results: Out of 3,753 BCs, 125 (3.3%) had CCNE1 amplification. A higher occurrence of CCNE1 amplification was noted in post-treatment (n=2,368) compared to treatment-naïve tumors (n=1,385; 4% vs 2.4%, p=0.007). CCNE1 amplification was less common in hormone receptor (HR)+/HER2- BCs (2%) compared to HER2+ (7.6%) and triple-negative (7.2%) tumors (p<0.001). BCs with CCNE1 amplification showed higher median FGA, indicating increased genomic instability. In primary BC, TP53 alterations were more frequent in CCNE1-amplified tumors (q<0.001), while CDH1 alterations were mutually exclusive (q<0.001) suggesting that lobular BCs rarely harbor CCNE1 amplification. Similar trends were seen in post-treatment samples. CCNE1 amplification detected at baseline was linked to shorter median rwPFS in HR+/HER2- metastatic BCs treated with CDK4/6 inhibitors plus endocrine therapy (8.8 vs 15.2 months in CCNE1-amplified [n=9] vs CCNE1-non amplified [n=402]; hazard ratio [HR] 2.82, 95% CI 1.38-5.75), and in HER2+ metastatic BCs treated with first-line THP regimen (7.3 vs 20.8 months in CCNE1-amplified [n=5] vs CCNE1-non amplified [n=106]; HR 3.1, 95% CI 1.24-7.87). In a CCNE1-amplified triple-negative cell model (HCC1569), treatment with the PKMYT1 inhibitor RP-6306 significantly reduced tumor growth. Conclusions: CCNE1 amplification in BCs is associated with greater genomic instability and characterizes a group of metastatic BCs with poor response to standard of care therapies. Novel therapies targeting CCNE1-amplified tumors are under evaluation in preclinical and clinical studies.

oncology
Screening for Amplification Genomic Loci and Genes Associated Prognosis in Gastric Cancer

Xiaohong Wang,Lianhai Zhang,Jiafu Ji

DOI: https://doi.org/10.3978/j.issn.2095-6959.2015.06.s119

2015-01-01

Abstract:Objective: We used a high-resolution array-based comparative genomic hybridization (aCGH) coupled with patient clinical information to identify prognosis-related genomic loci and genes. Methods: aCGH coupled with patient clinical information was applied to identify prognosisrelated loci and genes with high-frequency recurrent gains in 129 GC cases. The candidate loci and genes were validated using an independent cohort of 384 cases through branched DNA signal amplification analysis. Results: A copy number gain of three chromosome regions, namely, 8q22, 8q24and 20q11-q13, conferred poor survival for patients. In addition, MYC, TNFRSF11B, ESRP1, CSE1L and MMP9 were found to be well correlated. Further validation verified that only MYC and TNFRSF11B within 8q24 are related to survival. Patients with gains in both MYC and TNFRSF11B presented poorer survival than those with no gains, particularly those with non-cardia GC. Gains in both of these genes were also a significant independent prognostic indicator. Conclusion: Copy number gains in MYC and TNFRSF11B located at 8q24are associated with survival in GC, particularly noncardia GC.
Clinical Impact of 11q13.3 Amplification on Immune Cell Infiltration and Prognosis in Breast Cancer

Renyu Zhou,Xiaoxi Zhu,Yulong Peng,Lijuan Zhong,Lilin Peng,Bo Yang,Yuhua Meng,Xuanzhao Chen,Yuanzhi Lu

DOI: https://doi.org/10.2147/IJGM.S360177

IF: 2.145

2022-04-14

International Journal of General Medicine

Abstract:Renyu Zhou, 1 Xiaoxi Zhu, 2 Yulong Peng, 1 Lijuan Zhong, 1 Lilin Peng, 1 Bo Yang, 1 Yuhua Meng, 3 Xuanzhao Chen, 4 Yuanzhi Lu 1, 4 1 Department of Pathology, First Affiliated Hospital of Jinan University, Guangzhou, 510630, People's Republic of China; 2 Department of Oncology, First Affiliated Hospital of Jinan University, Guangzhou, 510630, People's Republic of China; 3 Department of Pathology, Shunde Hospital, Southern Medical University (The First People's Hospital of Shunde), Foshan, 528300, People's Republic of China; 4 The Center of Pathological Diagnosis and Research, Affiliated Hospital of Guangdong Medical University, Zhanjiang, 524023, People's Republic of China Correspondence: Yuanzhi Lu, Tel +86-20 38688984, Email Introduction: Amplification of the 11q13.3 locus has been observed in various tumors. This study sought to determine the correlation of gene amplification at the 11q13.3 locus with the immune status and survival of breast cancer. Methods: Amplification of the 11q13.3 locus was characterized by analyzing a publicly available database from the cBioPortal platform (TCGA). The correlation of amplified genes with immune cell infiltration in breast cancer was further analyzed using the TIMER2.0 platform. Immunohistochemical staining was used to determine the expression levels of Cyclin D1 (CCND1), Fas-associated death domain (FADD) and P53 in 156 clinical breast cancer samples. Results: This study revealed that amplification of the 11q13.3 amplicon in breast cancer is likely more frequently detected in luminal B breast cancer. Moreover, high expression or amplification of CCND1 , fibroblast growth factor 3 ( FGF3 ), fibroblast growth factor 4 ( FGF4 ), fibroblast growth factor 19 ( FGF19 ) and FADD was inversely correlated with the abundance of CD4+ T cells and dendritic cell infiltration in breast cancer ( P < 0.05). Data analysis also demonstrated that high expression of CCND1, FGF4 and FADD mRNA levels was closely correlated with shorter recurrence-free survival (RFS) in patients with breast cancer ( P < 0.05). The results of immunohistochemical staining from clinical samples further confirmed that high expression of CCND1 and FADD was frequently detected in luminal B and high-grade breast cancer with shorter metastasis-free survival times ( P < 0.05). Conclusion: This study demonstrated that coamplification of genes located on the 11q13.3 amplicon is frequently detected in luminal B subtype breast cancer and is closely associated with worse survival in patients with breast cancer. Moreover, coamplification of the CCND1-FGF locus might decrease antitumor immune activity in breast cancer, indicating that coamplification of the 11q13.3 amplicon is likely to be a key determinant of therapeutic resistance and accelerate the aggressive evolution of breast cancer. Keywords: breast cancer, chromosomal amplification, 11q13.3 amplicon, prognosis, immune microenvironment Breast cancer (BC) is a malignant tumor with a high incidence in women worldwide, threatening women's health and lives, and it has become the "first killer" that endangers women's health. 1 Its incidence is accelerating globally and tends to be detected younger. 2–4 Early studies based on the results of mRNA profiling divided breast cancer into five intrinsic subtypes: luminal A, luminal B, HER2-enriched, basal cell-like and normal breast-like subtypes. 5 Clinically, immunohistochemical detection of ER, PR, HER2 and Ki67 can roughly distinguish the intrinsic subtypes of breast cancer and guide adjuvant therapy with anti-endocrine or targeting regimens such as chemotherapy plus tamoxifen or fulvestrant for ER+/PR+ breast cancer and trastuzumab or pertuzumab for HER2-enriched subtypes of breast cancer. However, approximately 30–40% of breast cancer patients develop primary and/or acquired drug-resistant recurrence and ultimately metastasis to bones, lungs, liver and brain. It has been demonstrated that different oncogenic driver alterations may contribute to recurrence or metastasis in different subtypes of breast cancer, highlighting that driver mutations of PIK3CA (phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha), ESR1 (estrogen receptor 1), AKT1 (AKT serine/threonine kinase 1) and GATA3 (GATA binding protein 3) as well as inactivation of PTEN (phosphatase and tensin homolog) and NF1 (neurofibromin 1) are frequently present in metastatic hormone receptor (HR)-positive breast cancer. 6,7 Additional -Abstract Truncated-
A comprehensive analysis of candidate genes in familial pancreatic cancer families reveals a high frequency of potentially pathogenic germline variants

Julie Earl,Cristina Galindo-Pumariño,Jessica Encinas,Emma Barreto,Maria E Castillo,Vanessa Pachón,Reyes Ferreiro,Mercedes Rodríguez-Garrote,Silvia González-Martínez,Teresa Ramon Y Cajal,Luis Robles Diaz,Isabel Chirivella-Gonzalez,Montse Rodriguez,Eva Martínez de Castro,David García-Seisdedos,Gloria Muñoz,Juan Manuel Rosa Rosa,Mirari Marquez,Nuría Malats,Alfredo Carrato

DOI: https://doi.org/10.1016/j.ebiom.2020.102675

IF: 11.205

EBioMedicine

Abstract:Background: The 5-year survival rate of patients with pancreatic ductal adenocarcinoma (PDAC) is around 5% due to the fact that the majority of patients present with advanced disease that is treatment resistant. Familial pancreatic cancer (FPC) is a rare disorder that is defined as a family with at least two affected first degree relatives, with an estimated incidence of 4%-10%. The genetic basis is unknown in the majority of families although around 10%-13% of families carry germline mutations in known genes associated with hereditary cancer and pancreatitis syndromes. Methods: Panel sequencing was performed of 35 genes associated with hereditary cancer in 43 PDAC cases from families with an apparent hereditary pancreatic cancer syndrome. Findings: Pathogenic variants were identified in 19% (5/26) of PDAC cases from pure FPC families in the genes MLH1, CDKN2A, POLQ and FANCM. Low frequency potentially pathogenic VUS were also identified in 35% (9/26) of PDAC cases from FPC families in the genes FANCC, MLH1, PMS2, CFTR, APC and MUTYH. Furthermore, an important proportion of PDAC cases harboured more than one pathogenic, likely pathogenic or potentially pathogenic VUS, highlighting the multigene phenotype of FPC. Interpretation: The genetic basis of familial or hereditary pancreatic cancer can be explained in 21% of families by previously described hereditary cancer genes. Low frequency variants in other DNA repair genes are also present in 35% of families which may contribute to the risk of pancreatic cancer development. Funding: This study was funded by the Instituto de Salud Carlos III (Plan Estatal de I + D + i 2013-2016): ISCIII (PI09/02221, PI12/01635, PI15/02101 and PI18/1034) and co-financed by the European Development Regional Fund ''A way to achieve Europe'' (ERDF), the Biomedical Research Network in Cancer: CIBERONC (CB16/12/00446), Red Temática de investigación cooperativa en cáncer: RTICC (RD12/0036/0073) and La Asociación Española contra el Cáncer: AECC (Grupos Coordinados Estables 2016).
Characterizing PALB2 intragenic duplication breakpoints in a triple-negative breast cancer case using long-read sequencing

Iulian O. Ban,Alice Chabert,Thomas Guignard,Jacques Puechberty,Simon Cabello-Aguilar,Pascal Pujol,Julie A. Vendrell,Jérôme Solassol

DOI: https://doi.org/10.3389/fonc.2024.1355715

IF: 4.7

2024-02-29

Frontiers in Oncology

Abstract:Introduction: Accurate identification and characterization of Large Genomic Rearrangements (LGR), especially duplications, are crucial for precise diagnosis and risk assessment. In this report, we characterized an intragenic duplication breakpoint of PALB2 to determine its pathogenicity significance. Methods: A 52-year-old female with triple-negative breast cancer was diagnosed with a novel PALB2 LGR. An efficient and accurate methodology was applied, combining long-read sequencing and transcript analysis for the rapid characterization of the duplication. Results: Duplication of exons 5 and 6 of PALB2 was validated by transcript analysis. Long-read sequencing enabled the localization of breakpoints within Alu elements, providing insights into the mechanism of duplication via non-allelic homologous recombination. Conclusion: Using our combined methodology, we reclassified the PALB2 duplication as a pathogenic variant. This reclassification suggests a possible causative link between this specific genetic alteration and the aggressive phenotype of the patient.

oncology
Allele-Specific Amplification in Cancer Revealed by SNP Array Analysis.

T LaFramboise,BA Weir,XJ Zhao,R Beroukhim,C Li,D Harrington,WR Sellers,M Meyerson

DOI: https://doi.org/10.1371/journal.pcbi.0010065

2005-01-01

PLoS Computational Biology

Abstract:Amplification, deletion, and loss of heterozygosity of genomic DNA are hallmarks of cancer. In recent years a variety of studies have emerged measuring total chromosomal copy number at increasingly high resolution. Similarly, loss-of-heterozygosity events have been finely mapped using high-throughput genotyping technologies. We have developed a probe-level allele-specific quantitation procedure that extracts both copy number and allelotype information from single nucleotide polymorphism (SNP) array data to arrive at allele-specific copy number across the genome. Our approach applies an expectation-maximization algorithm to a model derived from a novel classification of SNP array probes. This method is the first to our knowledge that is able to (a) determine the generalized genotype of aberrant samples at each SNP site (e.g., CCCCT at an amplified site), and (b) infer the copy number of each parental chromosome across the genome. With this method, we are able to determine not just where amplifications and deletions occur, but also the haplotype of the region being amplified or deleted. The merit of our model and general approach is demonstrated by very precise genotyping of normal samples, and our allele-specific copy number inferences are validated using PCR experiments. Applying our method to a collection of lung cancer samples, we are able to conclude that amplification is essentially monoallelic, as would be expected under the mechanisms currently believed responsible for gene amplification. This suggests that a specific parental chromosome may be targeted for amplification, whether because of germ line or somatic variation. An R software package containing the methods described in this paper is freely available at http://genome.dfci.harvard.edu/~tlaframb/PLASQ.
Metastatic susceptibility locus, an 8p hot-spot for tumour progression disrupted in colorectal liver metastases: 13 candidate genes examined at the DNA, mRNA and protein level

Donia P Macartney-Coxson,Kylie A Hood,Hong-jun Shi,Teresa Ward,Anna Wiles,Rosemary O'Connor,David A Hall,Rod A Lea,Janice A Royds,Richard S Stubbs,Serena Rooker

DOI: https://doi.org/10.1186/1471-2407-8-187

IF: 4.638

2008-07-01

BMC Cancer

Abstract:Background: Mortality from colorectal cancer is mainly due to metastatic liver disease. Improved understanding of the molecular events underlying metastasis is crucial for the development of new methods for early detection and treatment of colorectal cancer. Loss of chromosome 8p is frequently seen in colorectal cancer and implicated in later stage disease and metastasis, although a single metastasis suppressor gene has yet to be identified. We therefore examined 8p for genes involved in colorectal cancer progression. Methods: Loss of heterozygosity analyses were used to map genetic loss in colorectal liver metastases. Candidate genes in the region of loss were investigated in clinical samples from 44 patients, including 6 with matched colon normal, colon tumour and liver metastasis. We investigated gene disruption at the level of DNA, mRNA and protein using a combination of mutation, semi-quantitative real-time PCR, western blotting and immunohistochemical analyses. Results: We mapped a 2 Mb region of 8p21-22 with loss of heterozygosity in 73% of samples; 8/11 liver metastasis samples had loss which was not present in the corresponding matched primary colon tumour. 13 candidate genes were identified for further analysis. Both up and down-regulation of 8p21-22 gene expression was associated with metastasis. ADAMDEC1 mRNA and protein expression decreased during both tumourigenesis and tumour progression. Increased STC1 and LOXL2 mRNA expression occurred during tumourigenesis. Liver metastases with low DcR1/TNFRSF10C mRNA expression were more likely to present with extrahepatic metastases (p = 0.005). A novel germline truncating mutation of DR5/TNFRSF10B was identified, and DR4/TNFRSF10A SNP rs4872077 was associated with the development of liver metastases (p = 0.02). Conclusion: Our data confirm that genes on 8p21-22 are dysregulated during colorectal cancer progression. Interestingly, however, instead of harbouring a single candidate colorectal metastasis suppressor 8p21-22 appears to be a hot-spot for tumour progression, encoding at least 13 genes with a putative role in carcinoma development. Thus, we propose that this region of 8p comprises a metastatic susceptibility locus involved in tumour progression whose disruption increases metastatic potential.
Interplay between ESR1/PIK3CA codon variants, oncogenic pathway alterations and clinical phenotype in patients with metastatic breast cancer (MBC): comprehensive circulating tumor DNA (ctDNA) analysis

Lorenzo Gerratana,Andrew A. Davis,Marko Velimirovic,Katherine Clifton,Whitney L. Hensing,Ami N. Shah,Charles S. Dai,Carolina Reduzzi,Paolo D’Amico,Firas Wehbe,Arielle Medford,Seth A. Wander,William J. Gradishar,Amir Behdad,Fabio Puglisi,Cynthia X. Ma,Aditya Bardia,Massimo Cristofanilli,Paolo D'Amico,Cynthia X. Ma…

DOI: https://doi.org/10.1186/s13058-023-01718-0

2023-10-03

Breast Cancer Research

Abstract:although being central for the biology and druggability of hormone-receptor positive, HER2 negative metastatic breast cancer (MBC), ESR1 and PIK3CA mutations are simplistically dichotomized as mutated or wild type in current clinical practice.

oncology

Affine blocking sets, three-dimensional codes and the Griesmer bound

DRAFT DRAFT 1 Representing and Reasoning with Correlated Effects in Probabilistic Causal Models

[Analysis of the Mutations of BRCA1 in 9 Familiar Breast Cancer Patients].

Youth with disabilities' perspectives of the environment and participation: a qualitative meta-synthesis.

A Genome-Wide Association Study Identifies a New Ovarian Cancer Susceptibility Locus on 9P22.2.

Identification and functional analysis of 9p24 amplified genes in human breast cancer

Amplification of PVT1 Contributes to the Pathophysiology of Ovarian and Breast Cancer.

High-Resolution Genomic And Expression Analyses Of Copy Number Alterations In Breast Tumors

A novel RBBP8(p.E281*) germline mutation is a predisposing mutation in familial hereditary cancer syndrome

5' Region Large Genomic Rearrangements in the BRCA1 Gene in French Families: Identification of a Tandem Triplication and Nine Distinct Deletions with Five Recurrent Breakpoints

Alu–Mediated Duplication and Deletion of Exon 11 Are Frequent Mechanisms of PALB2 Inactivation, Predisposing Individuals to Hereditary Breast–Ovarian Cancer Syndrome

Functional Analysis and Fine Mapping of the 9p22.2 Ovarian Cancer Susceptibility Locus

A Molecular Characterization of the Allelic Expression of the BRCA1 Founder Δ9–12 Pathogenic Variant and Its Potential Clinical Relevance in Hereditary Cancer

CCNE1 amplification as marker of poor prognosis and novel therapeutic target in advanced breast cancer.

Screening for Amplification Genomic Loci and Genes Associated Prognosis in Gastric Cancer

Clinical Impact of 11q13.3 Amplification on Immune Cell Infiltration and Prognosis in Breast Cancer

A comprehensive analysis of candidate genes in familial pancreatic cancer families reveals a high frequency of potentially pathogenic germline variants

Characterizing PALB2 intragenic duplication breakpoints in a triple-negative breast cancer case using long-read sequencing

Allele-Specific Amplification in Cancer Revealed by SNP Array Analysis.

Metastatic susceptibility locus, an 8p hot-spot for tumour progression disrupted in colorectal liver metastases: 13 candidate genes examined at the DNA, mRNA and protein level

Interplay between ESR1/PIK3CA codon variants, oncogenic pathway alterations and clinical phenotype in patients with metastatic breast cancer (MBC): comprehensive circulating tumor DNA (ctDNA) analysis